SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending due to concerns about increased spending on AI and infrastructure, despite strong revenue growth and a one-time tax charge impacting EPS. The community is debating whether the sell-off is an overreaction and a buying opportunity, or a sign of weakening profitability and a shift in investor sentiment. Some traders are anticipating a bounce back to the 50-day moving average, while others see further downside potential.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending due to renewed discussions around antimony supply and potential impacts from trade relations, particularly regarding export controls from China and a recently rejected acquisition offer. Community members are weighing the implications of these factors on the company's future, discussing the possibility of a short squeeze, and the potential for government support to bolster domestic antimony production.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet's stock is trending as strong AI demand and advertising growth drove its Q3 revenue above expectations, prompting increased capital expenditure forecasts and community excitement. Investors are reacting positively to Alphabet's favored cash flow strategy and AI investments, while some analysts are predicting further gains. Community members are actively discussing the stock's potential to reach new price levels and its long-term investment value.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending due to concerns about slowing growth and reduced guidance, sparking debate about its valuation and future prospects. Community discussions center on whether the brand is losing its value proposition amid rising prices and inconsistent portions, with some criticizing the CEO's handling of the situation. Investors are weighing whether the dip presents a buying opportunity or signals deeper issues within the company and the broader consumer discretionary sector.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending as traders discuss potential catalysts from upcoming conferences and strong revenue growth in the obesity sector from competitors. The community speculates about buyout possibilities, comparing VKTX's assets and market cap to recent acquisitions in the space. Bullish sentiment remains high due to positive clinical data and analysts' price targets.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending amid mixed reactions to its earnings, with analysts debating the impact of AI spending on future growth; despite strong cloud performance, some express concerns about increased capital expenditures. Community discussions revolve around whether the company's valuation remains justified in light of its AI investments and competition in the cloud sector, with some speculating on a potential post-earnings dip.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox ($RBLX) is trending amid discussions around its Q3 earnings report, which showed higher revenue and lower EPS than expected, alongside FY25 bookings guidance. The community is actively debating the company's valuation and future prospects, while some express concerns related to broader market conditions and commentary around the platform's content.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending amid positive sentiment driven by AI advancements and anticipation of strong earnings, with the community discussing potential for the stock to reach new highs. Upgrades from analysts and excitement around cloud and AI revenue are fueling optimism, although some traders are wary of a potential pullback after recent gains. Additionally, a new partnership between Google and NextEra Energy to restart a nuclear plant in Iowa is generating some buzz.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending due to strong Q3 earnings, driven by high demand for weight loss drugs Mounjaro and Zepbound, which beat revenue expectations and raised the FY25 guidance. The community is focused on the impact of this GLP-1 momentum, potential FDA approvals, and the company's strategic partnerships in AI, viewing LLY as a leader in the pharmaceutical sector.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to significant after-hours momentum, with community members highlighting its low float and potential for a short squeeze, reminiscent of other recent runners. Traders are actively discussing entry points, price targets, and potential overnight holds, while also pointing to contracts of nearly $100 million. Despite the excitement, some caution against chasing the pump, noting the stock's volatile history.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wedbush on Friday raised its price target on Artiva Biotherapeutics, Inc. (ARTV) to $23 from $18 while keeping an ‘Outperform’ rating on the shares.The new price target implies a potential upside of 730% to the stock’s closing price on Thursday. Shares of the company rallied 99% on Friday at the time of writing.The price target hike <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/16/3168298/0/en/artiva-biotherapeutics-announces-refractory-rheumatoid-arthritis-as-lead-indication-upcoming-data-releases-and-corporate-update.html">follows</a> the company’s announcement on Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its cell therapy candidate AlloNK for the treatment of refractory rheumatoid arthritis in combination with Rituximab. The company also said that it has prioritized refractory rheumatoid arthritis as the lead indication for AlloNK.“Despite the many approved therapies in RA, there are over 100,000 patients in the United States who remain treatment refractory and could potentially benefit from a deep B-cell depleting therapy,” CEO Fred Aslan explained.Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects over 1.5 million people in the United States and can cause painful joint inflammation, progressive joint damage, and disability. A significant subset becomes refractory and no longer responds to or tolerates available treatment options.The company now plans to share safety and translational data for AlloNK in mid-November from patients treated with AlloNK and Rituximab across multiple autoimmune diseases, followed by clinical response data in the first half of 2026 from over 15 refractory RA patients. The CEO also added that the company is planning interactions with the FDA in the first half of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARTV">ARTV stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:588/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_10_20_08_AM_png_e279bf0c53.webp" alt="ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="62"><figcaption>ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rally further.<stembedurl>https://stocktwits.com/bzspy/message/632725500</stembedurl>ARTV stock is down by 45% this year and by 57% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-supervised-autonomy-analyst-warns-ahead-q3-earnings-valuation-177x-pe/ch6rM5XR3Fe">Tesla Still In ‘Supervised Autonomy,’ Says Analyst As Q3 Earnings Day Nears: ‘Shouldn’t Trade At 177x P/E’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.

Equity

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.


Shares of PepGen (PEPG) more than doubled on Thursday morning after multiple analysts raised their price targets on the stock following the release of positive clinical data from an early-stage study in patients with myotonic dystrophy type 1.Wedbush raised its price target on PepGen to $9 from $7 and kept an ‘Outperform’ rating on the shares, while H.C. Wainwright hiked its price target on the stock to $12 from $8.Myotonic dystrophy type 1 (DM1) is a progressive disorder that primarily affects skeletal, cardiac, and smooth muscle. It is estimated to affect about 40,000 patients in the U.S.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.pepgen.com/news-releases/news-release-details/pepgen-announces-highest-mean-splicing-correction-reported-dm1">announced</a> on Wednesday that a 53.7% mean splicing correction was observed in DM1 patients following a single 15 mg/kg dose of its PGN-EDODM1, which is higher than any previously reported splicing correction in DM1 patients. All patients who received the dose in the trial showed an improvement in splicing correction, the company noted.“Since mis-splicing is the underlying cause of DM1, we believe high levels of splicing correction have the potential to reverse the underlying molecular defects, and produce functional improvements in multiple outcome measures, including myotonia and muscle weakness, in repeat dose studies,” said Paul Streck, Executive Vice President of Research and Development at PepGen.The company previously reported mean splicing correction of 12.3% and 29.1%, respectively, with 5mg/kg and 10mg/kg doses of PGN-EDODM1.The investigational candidate was well-tolerated at a dose of 15 mg/kg, and no serious treatment-related adverse events were identified, the company stated. However, one patient had to receive oral antihistamines for treatment-related adverse events, it said.PepGen's nearly 54% correction sets a new benchmark and "strongly suggests that repeat dosing could yield clinically meaningful functional benefit," contends H.C. Wainwright.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PEPG">PEPG stock </a>rose from 'neutral' to 'extremely bullish' territory over the past 24 hours, while message volume stayed at 'extremely high' levels.&nbsp;PEPG stock is up 51% this year but down approximately 34% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/carmax-stock-tumbles-after-q2-earnings/chDlO6OR348">Why Did CarMax Stock Tumble 24% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PepGen Stock More Than Doubles On Thursday – Check Out The New Price Targets On Wall Street

Wedbush raised its price target on PepGen to $9 from $7 and kept an ‘Outperform’ rating on the shares, while H.C. Wainwright hiked its price target on the stock to $12 from $8.

Shares of genetics research company 23andMe Holding Co, which recently filed for bankruptcy, notched its best session ever on Thursday after obtaining a legal nod to start an asset sale.Late on Wednesday, 23andMe said it had secured a U.S. bankruptcy court approval for its initial Chapter 11 motions, including wage payments, vendor compensation, and a $35-million debtor-in-possession financing agreement with JMB Capital Partners.&nbsp;The court also authorized a sale process for most of its assets, requiring buyers to adhere to 23andMe's consumer privacy policies.&nbsp;The company, working with Moelis, will solicit bids over 45 days. A second hearing on further relief, including final approval of the financing facility, is set for April 22.The news sent 23andMe's stock soaring more than 45% on Thursday, although it slid in after-hours trading.On Stocktwits, message volume about 23andMe has surged by over 26,000%, while its following has grown by 4% since the company filed for bankruptcy during the weekend.Sentiment on the platform shifted from 'bearish' to 'extremely bullish' in a day.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/ME_sentiment_and_message_volume_as_of_March_27_png_50af800a78.webp" alt="ME sentiment and message volume as of March 27.png" width="1318" height="302"><figcaption>ME sentiment and message volume as of March 27. | source: Stocktwits</figcaption></figure>Retail investors speculated on potential buyouts, including one from co-founder Anne Wojcicki, who stepped down as CEO after the bankruptcy filing to pursue a takeover as "an independent bidder."One user estimated the company's genetic data alone could be worth over $1 billion, suggesting a buyout in the "$3-$5 range”&nbsp;per share.They also argued that even at a lowball valuation of $10 per user, the company could still be worth $100 million after debt, making it an attractive acquisition target.<stembedurl>https://stocktwits.com/SWIMHOLE/message/609440102</stembedurl>Another saw a Wojcicki buyout as unlikely and speculated that Big Pharma, international buyers, or even Chinese biotech firm BGI could become potential acquirers.<stembedurl>https://stocktwits.com/Jack_du/message/609505055</stembedurl>Retail investors also cited a media&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thetimes.com/business-money/companies/article/british-investor-backs-rescue-of-failing-genetics-firm-23andme-swl58rsqs">report</a> about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue effort."We believe this business is not only salvageable but could be worth over a billion dollars if the right changes are made," he reportedly said.23andMe, founded in 2006 by Wojcicki, Linda Avey, and Paul Cusenza, quickly became one of the hottest biotech startups with its DNA testing services that let users explore their ancestry and genetic traits through simple "spit kits" mailed to their homes.The company went public via a blank-check merger in 2021, at the height of the COVID-19 pandemic, reaching a peak market capitalization of $6 billion.&nbsp;However, by 2024, its valuation had plummeted to just $120 million as it struggled to churn a profit despite amassing a customer base of 15 million.Following its bankruptcy filing, 23andMe's login portal crashed Monday evening as users rushed to delete their genetic data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view of 23andMe headquarters in Sunnyvale, California, United States on March 25, 2025. (Photo by Tayfun Coskun/Anadolu via Getty Images)

Lifeline For 23andMe? Stock Jumps After Court Greenlights Bankruptcy Asset Sale, Retail Weighs Possible Rescue Deals

Stocktwits users spotted a media report about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue effort.

Tonix Pharmaceuticals saw its shares swing wildly between gains and losses on Wednesday morning as they started to trade following a 1-for-100 reverse stock split announced at the start of this week.&nbsp;The move aims to meet the Nasdaq's $1.00 minimum bid price requirement for continued listing.On Stocktwits, Tonix emerged as the most active biotech stock by message volume over the past 24 hours, but sentiment shifted from 'bullish' to 'neutral.'&nbsp;One popular post highlighted legal concerns, with the user accusing Tonix of manipulative practices such as "multiple RS [reverse stock splits] in a short time frame" and "lack of disclosures."A more optimistic user pointed to the Prescription Drug User Fee Act (PDUFA) goal date of Aug. 15, 2025, for FDA approval of Tonix's TNX-102 SL to treat fibromyalgia and the company's $10 million stock buyback announced in September as positive signs.<stembedurl>https://stocktwits.com/Camlandia/message/602920803</stembedurl><stembedurl>https://stocktwits.com/WARBUD/message/602912879</stembedurl>Tonix has reportedly executed multiple reverse stock splits in recent years, including in June 2024, May 2023, and May 2022, signaling a pattern of trying to maintain a minimum share price.&nbsp;The company's portfolio is focused on central nervous system disorders,&nbsp;prioritizing advancing TNX-102 SL.In December, the FDA&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/tnxp-stocktwits-chatter-explodes-after-fda-nod-for-nda/cJaVYSzR1F">accepted</a> the New Drug Application (NDA) for TNX-102 SL for fibromyalgia, which is also under a separate study for acute stress reaction and acute stress disorder.Earlier in 2024, Tonix reaffirmed its commitment to developing a&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/tnxp-stocktwits-chatter-explodes-after-fda-nod-for-nda/cJaVYSzR1F">mpox</a> vaccine, signaling its diversified approach to product development.Short interest in the stock has grown steadily since mid-December, rising from 0.9% to 8.5% by the end of January, according to Koyfin data.&nbsp;However, retail interest has also surged over the last three months, with Stocktwits message volume increasing by 1,750% and following jumping by nearly 10%.&nbsp;During that period, Tonix's stock price has gained more than 5%, although it has lost nearly 98% of its value over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Tonix Pharma Dominates Retail Biotech Buzz After 1-for-100 Reverse Split, Sentiment Turns Neutral Amid Volatility 

Short interest in the stock has grown steadily since mid-December, rising from 0.9% to 8.5% by the end of January, according to Koyfin data. 

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in&nbsp;almost three weeks, drawing heavy interest from retail traders.The surge followed news of a $27 million funding deal to fund the company’s planned purchase of Hope clinics.NRx’s Hope Therapeutics unit announced a stock purchase agreement with Smith &amp; Sauer, a private investment firm specializing in healthcare and technology investments.&nbsp;The agreement includes an immediate $2 million investment in NRx common stock and a $25 million purchase of Hope’s Series A preferred shares, with $6.75 million due by Feb. 7 and the remainder by April 1.&nbsp;The funds will be used to expand Interventional Psychiatry Clinics focused on treating severe depression and other psychological disorders.Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.&nbsp;He added that the company had initiated a financial advisory relationship to raise an additional $400 million for broader expansion.&nbsp;"Psychedelic Medications such as ketamine, neuromodulation technologies such as TMS, and digital therapeutics have sparked a revolution in psychiatry where for the first time patients with life threatening conditions such as depression and PTSD hope for a brighter future,” he said.Retail traders on Stocktwits took note, with message volume surging 94% on Tuesday and remaining at high levels ahead of Wednesday’s market open.&nbsp;Sentiment on the stock turned ‘bullish,’ with investors speculating on the impact of the projected $100 million revenue on earnings and share price.&nbsp;One user even predicted that the stock could more than double from current levels.<stembedurl>https://stocktwits.com/jonny80s/message/601877421</stembedurl><stembedurl>https://stocktwits.com/TheRealBomb/message/601781798</stembedurl>Despite losing 11% in value over the past year, NRx Pharmaceuticals has seen a 177% gain in the past three months, driven by increasing retail interest.&nbsp;The company’s follower count on Stocktwits has risen 3% over the last 12 months, while message volume has jumped 188%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding 

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 

BeiGene (<a class="mention" data-mention="$BGNE" data-symbol-id="BGNE" href="https://stocktwits.com/symbol/BGNE" target="_blank">$BGNE</a>) shares jumped over 5% pre-market Wednesday, with the oncology company’s stock poised to reach a two-week high after the European Commission approved its drug Tevimbra (Tislelizumab) for first-line treatment of gastric and esophageal cancers.The approval allows Tevimbra, in combination with chemotherapy, to treat esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction adenocarcinoma.&nbsp;Clinical trial data showed that Tevimbra improved median overall survival to 17.2 months versus 10.6 months with chemotherapy alone, demonstrating statistically significant and clinically meaningful benefits.Mark Lanasa, Chief Medical Officer for Solid Tumors at BeiGene, emphasized Tevimbra’s role as the cornerstone of the company’s solid tumor portfolio, noting that more than 1.3 million patients worldwide have been treated with the drug.&nbsp;The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.Esophageal cancer, which accounts for over 90% of esophageal squamous cell carcinoma cases, is one of the deadliest cancers. Beigene says it is projected to increase by nearly 60% to 957,000 annual cases by 2040, highlighting the urgent need for better treatment options.BeiGene has been expanding rapidly, recently reporting $1 billion in quarterly revenue, driven by U.S. and European product sales, and opening an $800 million R&amp;D and manufacturing facility in New Jersey.&nbsp;The company had also announced plans to rebrand as “BeOne Medicines Ltd.” and change its ticker to “ONC” following shareholder approval, signaling its commitment to global oncology leadership.<figure class="image"><a href="https://stocktwits.com/symbol/BGNE"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BGNE_sentiment_and_message_volume_Nov_27_premarket_749418ab8f.png" alt="BGNE sentiment and message volume Nov 27 premarket.png" width="1318" height="318"></a><figcaption>BGNE sentiment and message volume Nov 27 premarket as of 7:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment shifted from ‘neutral’ to ‘extremely bullish’ early on Wednesday following the approval news, accompanied by a surge in message volume.&nbsp;TD Cowen recently reiterated a ‘Buy’ rating on BeiGene and raised its price target to $260, citing the company’s robust pipeline, which it described as among the best in biotech.BeiGene stock has gained more than 8% year-to-date.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aspi-stock-slides-after-fuzzy-panda-short-call/cJIWDFNRWc">ASP Isotopes Stock Fizzles After Fuzzy Panda Short Call: Retail Eyes Opportunity</a>

Clinical trial data showed that Tevimbra improved median overall survival to 17.2 months versus 10.6 months with chemotherapy alone.

BeiGene Stock Eyes 2-Week High After EU Approves Cancer Treatment: Retail Enthusiasm Grows

The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.

Palumbo Wealth Management LLC Makes New $228,000 Investment in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)

Palumbo Wealth Management LLC acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Free Report) in the fourth quarter, according to its most recent disclosure with...

ProShares Ultra Nasdaq Biotechnology (BIB, $56.85) Stochastic Oscillator left the overbought zone on April 01, 2024

This is a signal that BIB's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

ProShares Ultra Nasdaq Biotechnology (BIB, $56.85) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that BIB's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Update

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB  Get Free Report) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 55,700...

BIB
ProShares Ultra Nasdaq Biotechnology

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest BIB News

BIBProShares Ultra Nasdaq Biotechnology